Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

A prospective, randomized, double-blind, controlled trial

Kyo Sang Yoo, Kyung Rim Huh, Yu Jin Kim, Kyoung Oh Kim, Cheol Hee Park, Taeho Hahn, Sang Hoon Park, Jong Hyeok Kim, Choong Kee Park, Young Jun Kwon, Glen Lehman

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVES: Pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic nafamostat mesilate, a synthetic protease inhibitor, would reduce the frequency and severity of post-ERCP pancreatitis. METHODS: A total of 286 patients were randomized to receive either intravenous nafamostat mesilate or placebo 60 minutes before ERCP and for 6 hours after ERCP. A database was prospectively collected by a defined protocol. Standardized criteria were used to diagnose and grade the severity of pancreatitis. RESULTS: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 5.9%. It occurred in 4 (2.8%) of 143 patients in the nafamostat group and in 13 (9.1%) of 143 patients in the control group (P = 0.03). Pancreatitis was graded mild in 2.1% and moderate in 0.7% of the nafamostat group and mild in 7.0% and moderate in 2.1% of the control group. There was no significant difference between the groups in the severity of pancreatitis. CONCLUSIONS: Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalPancreas
Volume40
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Endoscopic Retrograde Cholangiopancreatography
Pancreatitis
Control Groups
nafamostat
Reducing Agents
Incidence
Protease Inhibitors
Placebos
Demography
Databases

Keywords

  • endoscopic retrograde cholangiopancreatography
  • nafamostat mesilate
  • pancreatitis
  • prevention

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis : A prospective, randomized, double-blind, controlled trial. / Yoo, Kyo Sang; Huh, Kyung Rim; Kim, Yu Jin; Kim, Kyoung Oh; Park, Cheol Hee; Hahn, Taeho; Park, Sang Hoon; Kim, Jong Hyeok; Park, Choong Kee; Kwon, Young Jun; Lehman, Glen.

In: Pancreas, Vol. 40, No. 2, 03.2011, p. 181-186.

Research output: Contribution to journalArticle

Yoo, Kyo Sang ; Huh, Kyung Rim ; Kim, Yu Jin ; Kim, Kyoung Oh ; Park, Cheol Hee ; Hahn, Taeho ; Park, Sang Hoon ; Kim, Jong Hyeok ; Park, Choong Kee ; Kwon, Young Jun ; Lehman, Glen. / Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis : A prospective, randomized, double-blind, controlled trial. In: Pancreas. 2011 ; Vol. 40, No. 2. pp. 181-186.
@article{a95d2361800a44fe92d0038640fdf247,
title = "Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized, double-blind, controlled trial",
abstract = "OBJECTIVES: Pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic nafamostat mesilate, a synthetic protease inhibitor, would reduce the frequency and severity of post-ERCP pancreatitis. METHODS: A total of 286 patients were randomized to receive either intravenous nafamostat mesilate or placebo 60 minutes before ERCP and for 6 hours after ERCP. A database was prospectively collected by a defined protocol. Standardized criteria were used to diagnose and grade the severity of pancreatitis. RESULTS: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 5.9{\%}. It occurred in 4 (2.8{\%}) of 143 patients in the nafamostat group and in 13 (9.1{\%}) of 143 patients in the control group (P = 0.03). Pancreatitis was graded mild in 2.1{\%} and moderate in 0.7{\%} of the nafamostat group and mild in 7.0{\%} and moderate in 2.1{\%} of the control group. There was no significant difference between the groups in the severity of pancreatitis. CONCLUSIONS: Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis.",
keywords = "endoscopic retrograde cholangiopancreatography, nafamostat mesilate, pancreatitis, prevention",
author = "Yoo, {Kyo Sang} and Huh, {Kyung Rim} and Kim, {Yu Jin} and Kim, {Kyoung Oh} and Park, {Cheol Hee} and Taeho Hahn and Park, {Sang Hoon} and Kim, {Jong Hyeok} and Park, {Choong Kee} and Kwon, {Young Jun} and Glen Lehman",
year = "2011",
month = "3",
doi = "10.1097/MPA.0b013e3181f94d46",
language = "English",
volume = "40",
pages = "181--186",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

T2 - A prospective, randomized, double-blind, controlled trial

AU - Yoo, Kyo Sang

AU - Huh, Kyung Rim

AU - Kim, Yu Jin

AU - Kim, Kyoung Oh

AU - Park, Cheol Hee

AU - Hahn, Taeho

AU - Park, Sang Hoon

AU - Kim, Jong Hyeok

AU - Park, Choong Kee

AU - Kwon, Young Jun

AU - Lehman, Glen

PY - 2011/3

Y1 - 2011/3

N2 - OBJECTIVES: Pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic nafamostat mesilate, a synthetic protease inhibitor, would reduce the frequency and severity of post-ERCP pancreatitis. METHODS: A total of 286 patients were randomized to receive either intravenous nafamostat mesilate or placebo 60 minutes before ERCP and for 6 hours after ERCP. A database was prospectively collected by a defined protocol. Standardized criteria were used to diagnose and grade the severity of pancreatitis. RESULTS: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 5.9%. It occurred in 4 (2.8%) of 143 patients in the nafamostat group and in 13 (9.1%) of 143 patients in the control group (P = 0.03). Pancreatitis was graded mild in 2.1% and moderate in 0.7% of the nafamostat group and mild in 7.0% and moderate in 2.1% of the control group. There was no significant difference between the groups in the severity of pancreatitis. CONCLUSIONS: Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis.

AB - OBJECTIVES: Pancreatitis is the most common major complication of endoscopic retrograde cholangiopancreatography (ERCP). Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic nafamostat mesilate, a synthetic protease inhibitor, would reduce the frequency and severity of post-ERCP pancreatitis. METHODS: A total of 286 patients were randomized to receive either intravenous nafamostat mesilate or placebo 60 minutes before ERCP and for 6 hours after ERCP. A database was prospectively collected by a defined protocol. Standardized criteria were used to diagnose and grade the severity of pancreatitis. RESULTS: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 5.9%. It occurred in 4 (2.8%) of 143 patients in the nafamostat group and in 13 (9.1%) of 143 patients in the control group (P = 0.03). Pancreatitis was graded mild in 2.1% and moderate in 0.7% of the nafamostat group and mild in 7.0% and moderate in 2.1% of the control group. There was no significant difference between the groups in the severity of pancreatitis. CONCLUSIONS: Prophylactic intravenous nafamostat mesilate reduces the frequency of post-ERCP pancreatitis.

KW - endoscopic retrograde cholangiopancreatography

KW - nafamostat mesilate

KW - pancreatitis

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=79951724555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951724555&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181f94d46

DO - 10.1097/MPA.0b013e3181f94d46

M3 - Article

VL - 40

SP - 181

EP - 186

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 2

ER -